CA3173126A1 - Nucleic acid sequences encapsulated in lipid nanoparticles - Google Patents
Nucleic acid sequences encapsulated in lipid nanoparticles Download PDFInfo
- Publication number
- CA3173126A1 CA3173126A1 CA3173126A CA3173126A CA3173126A1 CA 3173126 A1 CA3173126 A1 CA 3173126A1 CA 3173126 A CA3173126 A CA 3173126A CA 3173126 A CA3173126 A CA 3173126A CA 3173126 A1 CA3173126 A1 CA 3173126A1
- Authority
- CA
- Canada
- Prior art keywords
- lipid
- aspects
- pharmaceutically acceptable
- lipid nanoparticle
- cedna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Plant Pathology (AREA)
- Optics & Photonics (AREA)
- Obesity (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063000990P | 2020-03-27 | 2020-03-27 | |
| US63/000,990 | 2020-03-27 | ||
| PCT/US2021/024413 WO2021195529A2 (en) | 2020-03-27 | 2021-03-26 | Novel lipids and nanoparticle compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3173126A1 true CA3173126A1 (en) | 2021-09-30 |
Family
ID=77890624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3173126A Pending CA3173126A1 (en) | 2020-03-27 | 2021-03-26 | Nucleic acid sequences encapsulated in lipid nanoparticles |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US12534435B2 (https=) |
| EP (1) | EP4125821A4 (https=) |
| JP (2) | JP7746280B2 (https=) |
| KR (1) | KR20220160647A (https=) |
| CN (1) | CN115916163A (https=) |
| AU (1) | AU2021241696A1 (https=) |
| BR (1) | BR112022019369A2 (https=) |
| CA (1) | CA3173126A1 (https=) |
| IL (1) | IL296763B2 (https=) |
| MX (1) | MX2022011988A (https=) |
| WO (1) | WO2021195529A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024192528A1 (en) * | 2023-03-22 | 2024-09-26 | Nanovation Therapeutics Inc. | Ionizable anionic lipids |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113166783B (zh) | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| IL296763B2 (en) * | 2020-03-27 | 2026-04-01 | Generation Bio Co | New lipids and their nanoparticle compositions |
| MX2023000806A (es) * | 2020-07-17 | 2023-04-11 | Generation Bio Co | Métodos para encapsular polinucleótidos en tamaños reducidos de nanopartículas lipídicas y formulación novedosa de estos. |
| IL303195A (en) | 2020-11-25 | 2023-07-01 | Akagera Medicines Inc | Lipid nanoparticles for delivery of nucleic acids and related methods of use |
| WO2023054242A1 (ja) * | 2021-09-30 | 2023-04-06 | 日油株式会社 | 核酸をリンパ管内皮細胞に送達するために用いられる脂質ナノ粒子 |
| EP4452942A1 (en) * | 2021-12-20 | 2024-10-30 | Beam Therapeutics Inc. | Nanomaterials comprising disulfides |
| CN118973614A (zh) | 2022-03-28 | 2024-11-15 | 日油株式会社 | 用于向脾脏组织递送核酸的脂质纳米粒子以及使用其向脾脏组织递送核酸的方法 |
| EP4501361A4 (en) * | 2022-03-28 | 2026-01-28 | Nof Corp | Lipid nanoparticles for delivering nucleic acid to peripheral blood mononuclear cells, and a method for delivering nucleic acid to peripheral blood mononuclear cells using them |
| JPWO2023190170A1 (https=) | 2022-03-28 | 2023-10-05 | ||
| KR20240167871A (ko) | 2022-03-28 | 2024-11-28 | 니치유 가부시키가이샤 | 아릴 에스테르-함유 카르복실산의 제조 방법 및 양이온성 지질의 제조 방법 |
| EP4531819A2 (en) | 2022-05-25 | 2025-04-09 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| EP4555999A1 (en) | 2022-07-15 | 2025-05-21 | NOF Corporation | Lipid nanoparticle and method for producing same, nucleic acid-encapsulated lipid nanoparticle and method for producing same, and method for inducing acquired immunity in living body by using nucleic acid-encapsulated lipid nanoparticle |
| KR20250037535A (ko) | 2022-07-15 | 2025-03-17 | 니치유 가부시키가이샤 | 핵산-로딩된 지질 나노입자의 동결건조 조성물 |
| WO2024203660A1 (ja) | 2023-03-29 | 2024-10-03 | 国立大学法人東北大学 | 核酸内封脂質ナノ粒子の製造方法 |
| CN116082184B (zh) * | 2023-04-12 | 2023-06-30 | 山东大学 | 基于环己二胺的可电离脂质、脂质纳米颗粒及其制备方法与应用 |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025043146A2 (en) * | 2023-08-24 | 2025-02-27 | Molecular Axiom Inc. | Lipid nanoparticle compositions and methods of using same |
| WO2025124584A1 (zh) * | 2023-12-15 | 2025-06-19 | 厦门赛诺邦格生物科技股份有限公司 | 一种含二硫键的可降解阳离子脂质及其应用 |
| CN117964577B (zh) * | 2024-03-29 | 2024-06-21 | 天津全和诚生物技术有限公司 | 阳离子脂质化合物、其制备方法、包含其的组合物及应用 |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026070952A1 (ja) * | 2024-09-27 | 2026-04-02 | 日油株式会社 | ジスルフィド結合を有する化合物およびその製造方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| CA2289702C (en) | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| US7201898B2 (en) | 2000-06-01 | 2007-04-10 | The University Of North Carolina At Chapel Hill | Methods and compounds for controlled release of recombinant parvovirus vectors |
| US20030077829A1 (en) | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
| US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
| NZ592917A (en) | 2003-09-15 | 2012-12-21 | Protiva Biotherapeutics Inc | Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| US9005654B2 (en) | 2005-07-27 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Systems and methods for manufacturing liposomes |
| US20100015218A1 (en) | 2007-02-16 | 2010-01-21 | Vasant Jadhav | Compositions and methods for potentiated activity of biologically active molecules |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| AU2009238175C1 (en) | 2008-04-15 | 2023-11-30 | Arbutus Biopharma Corporation | Novel lipid formulations for nucleic acid delivery |
| JP5642673B2 (ja) | 2008-07-10 | 2014-12-17 | セリナ・セラピユーテイツクス・インコーポレーテツド | 不活性末端基を有するポリオキサゾリン類、保護された開始基から調製されるポリオキサゾリン類及び関連化合物 |
| EP2558074B1 (en) | 2010-04-08 | 2018-06-06 | The Trustees of Princeton University | Preparation of lipid nanoparticles |
| WO2011139911A2 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
| WO2012000104A1 (en) | 2010-06-30 | 2012-01-05 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| EA201390145A1 (ru) | 2010-08-20 | 2013-11-29 | Серулин Фарма Инк. | Конъюгаты, частицы, композиции и связанные с ними способы |
| JP4775523B1 (ja) * | 2010-10-05 | 2011-09-21 | トヨタ自動車株式会社 | 推定装置および推定方法 |
| EP2500434A1 (en) | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| CA2853685C (en) | 2011-11-04 | 2019-09-03 | Nitto Denko Corporation | Single use system for sterilely producing lipid-nucleic acid particles |
| JP6093710B2 (ja) | 2011-11-18 | 2017-03-08 | 日油株式会社 | 細胞内動態を改善したカチオン性脂質 |
| AR090906A1 (es) | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y procedimientos para la administracion de oligonucleotidos |
| EP4019506A1 (en) | 2013-12-19 | 2022-06-29 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| SMT202200502T1 (it) | 2014-06-25 | 2023-01-13 | Acuitas Therapeutics Inc | Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici |
| LT3313829T (lt) | 2015-06-29 | 2024-08-12 | Acuitas Therapeutics Inc. | Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui |
| IL307179A (en) | 2015-10-28 | 2023-11-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| MX378999B (es) | 2015-11-16 | 2025-03-10 | Hoffmann La Roche | Fosforamidita de agrupacion de n-acetilgalactosamina (galnac). |
| HRP20220652T1 (hr) | 2015-12-10 | 2022-06-24 | Modernatx, Inc. | Pripravci i postupci unosa terapijskih sredstava |
| EP3397613A1 (en) | 2015-12-30 | 2018-11-07 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| WO2017152149A1 (en) | 2016-03-03 | 2017-09-08 | University Of Massachusetts | Closed-ended linear duplex dna for non-viral gene transfer |
| WO2019188867A1 (ja) | 2018-03-27 | 2019-10-03 | 日油株式会社 | 細胞内動態を改善した新規カチオン性脂質 |
| JP7075256B2 (ja) * | 2018-03-28 | 2022-05-25 | 三菱重工業株式会社 | 配管の余寿命評価方法 |
| JP7700101B2 (ja) | 2019-09-06 | 2025-06-30 | ジェネレーション バイオ カンパニー | 閉端ｄｎａおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法 |
| IL296763B2 (en) | 2020-03-27 | 2026-04-01 | Generation Bio Co | New lipids and their nanoparticle compositions |
| MX2023000806A (es) | 2020-07-17 | 2023-04-11 | Generation Bio Co | Métodos para encapsular polinucleótidos en tamaños reducidos de nanopartículas lipídicas y formulación novedosa de estos. |
-
2021
- 2021-03-26 IL IL296763A patent/IL296763B2/en unknown
- 2021-03-26 CA CA3173126A patent/CA3173126A1/en active Pending
- 2021-03-26 MX MX2022011988A patent/MX2022011988A/es unknown
- 2021-03-26 CN CN202180037847.5A patent/CN115916163A/zh active Pending
- 2021-03-26 EP EP21776608.8A patent/EP4125821A4/en active Pending
- 2021-03-26 BR BR112022019369A patent/BR112022019369A2/pt unknown
- 2021-03-26 US US17/913,498 patent/US12534435B2/en active Active
- 2021-03-26 WO PCT/US2021/024413 patent/WO2021195529A2/en not_active Ceased
- 2021-03-26 AU AU2021241696A patent/AU2021241696A1/en active Pending
- 2021-03-26 JP JP2022558110A patent/JP7746280B2/ja active Active
- 2021-03-26 KR KR1020227037604A patent/KR20220160647A/ko active Pending
-
2024
- 2024-04-24 US US18/644,728 patent/US12252470B2/en active Active
-
2025
- 2025-01-31 US US19/042,351 patent/US20250361208A1/en active Pending
- 2025-09-17 JP JP2025154013A patent/JP2025181861A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024192528A1 (en) * | 2023-03-22 | 2024-09-26 | Nanovation Therapeutics Inc. | Ionizable anionic lipids |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230159459A1 (en) | 2023-05-25 |
| WO2021195529A2 (en) | 2021-09-30 |
| JP7746280B2 (ja) | 2025-09-30 |
| BR112022019369A2 (pt) | 2022-12-13 |
| JP2023518985A (ja) | 2023-05-09 |
| EP4125821A4 (en) | 2024-06-26 |
| IL296763B2 (en) | 2026-04-01 |
| US20240294474A1 (en) | 2024-09-05 |
| IL296763B1 (en) | 2025-12-01 |
| US12252470B2 (en) | 2025-03-18 |
| CN115916163A (zh) | 2023-04-04 |
| EP4125821A2 (en) | 2023-02-08 |
| AU2021241696A1 (en) | 2022-12-01 |
| KR20220160647A (ko) | 2022-12-06 |
| JP2025181861A (ja) | 2025-12-11 |
| MX2022011988A (es) | 2023-01-04 |
| US12534435B2 (en) | 2026-01-27 |
| IL296763A (en) | 2022-11-01 |
| WO2021195529A3 (en) | 2021-11-18 |
| US20250361208A1 (en) | 2025-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12252470B2 (en) | Lipids and nanoparticle compositions thereof | |
| IL323923A (en) | Ionizable lipids and nanoparticle compositions thereof | |
| US20240293574A1 (en) | Cationic lipids and compositions thereof | |
| US12263228B2 (en) | Lipids and compositions thereof | |
| US20230181764A1 (en) | Novel lipids and nanoparticle compositions thereof | |
| CN117545469A (zh) | 阳离子脂质及其组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220923 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241213 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250321 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250321 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250321 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250414 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250415 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250613 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250613 |